Tables

TABLE 1 AUTOINJECTOR MARKET REVENUE BY APPLICATION SEGMENTATION' 2017-2024 ($MILLION) 33
TABLE 2 PREVALENCE OF DIABETES POPULATION FORECASTING BY REGION 37
TABLE 3 AUTOINJECTOR MARKET REVENUE BY REGIONS' 2017-2024 ($MILLION) 44
TABLE 4 AMGEN INC.: OFFERINGS 51
TABLE 5 AMGEN INC.: RECENT DEVELOPMENTS 51
TABLE 6 BECTON DICKINSON AND COMPANY: OFFERINGS 58
TABLE 7 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS 58
TABLE 1 MYLAN N.V.: OFFERINGS 63
TABLE 2 MYLAN N.V.: RECENT DEVELOPMENTS 63
TABLE 3 BAYER AG: OFFERINGS 68
TABLE 4 BAYER AG: RECENT DEVELOPMENTS 68
TABLE 5 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 72
TABLE 6 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 73
TABLE 7 NOVARTIS AG: OFFERINGS 77
TABLE 8 NOVARTIS AG: RECENT DEVELOPMENTS 78
TABLE 9 YPSOMED HOLDING AG: SNAPSHOT 83
TABLE 10 YPSOMED HOLDING AG: RECENT DEVELOPMENTS 83
TABLE 11 BIOGEN PHARMACEUTICALS: OVERVIEW 84
TABLE 12 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS 84
TABLE 13 PFIZER INC. OVERVIEW 85
TABLE 14 PFIZER INC.: RECENT DEVELOPMENTS 86
TABLE 15 TEVA PHARMACEUTICAL INDUSTRIES LTD. OVERVIEW 87
TABLE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS 88
TABLE 17 ANTARES PHARMA' INC.: OVERVIEW 89
TABLE 18 ANTARES PHARMA' INC.: RECENT DEVELOPMENTS 89
TABLE 19 JOHNSON & JOHNSON: OVERVIEW 90
TABLE 20 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 90
TABLE 21 ABBVIE INC.: OVERVIEW 91
TABLE 22 ABBVIE INC.: RECENT DEVELOPMENTS 92

LIST OF FIGURE

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL AUTOINJECTOR MARKET 15
CHART 2 GLOBAL AUTOINJECTORS MARKET REVENUE' 2017-2024 ($MILLION) 18
CHART 3 SEGMENTATION OF GLOBAL AUTOINJECTOR MARKET 23
CHART 4 PORTER 5 FORCES OF GLOBAL AUTOINJECTOR MARKET 24
CHART 5 PEST ANALYSIS OF AUTOINJECTOR MARKET 26
CHART 6 MARKET DYNAMICS - DRO ANALYSIS 27
CHART 7 DRO - IMPACT ANALYSIS OF GLOBAL AUTOINJECTORS MARKET 32
CHART 8 KEY STAKEHOLDERS 33
CHART 9 AUTOINJECTOR MARKET SEGMENT REVENUE BY APPLICATION' 2017 VS 2024 ($ MILLION) 34
CHART 10 ANAPHYLAXIS AUTOINJECTOR MARKET REVENUE' BY APPLICATION SEGMENTATION 2017-2024 ($MILLION) 36
CHART 11 MULTIPLE SCLEROSIS AUTOINJECTOR MARKET REVENUE' BY APPLICATION SEGMENTATION 2017-2024 ($MILLION) 36
CHART 12 RHEUMATOID ARTHRITIS MARKET REVENUE' BY APPLICATION SEGMENTATION 2017-2024 ($MILLION) 37
CHART 13 DIABETES AUTOINJECTOR MARKET REVENUE' BY APPLICATION SEGMENTATION 2017-2024 ($MILLION) 39
CHART 14 OTHERS AUTOINJECTOR MARKET REVENUE' BY APPLICATION SEGMENTATION' 2017-2024 ($MILLION) 40
CHART 15 AUTOINJECTOS MARKET SEGMENT SHARE BY TYPE SEGMENTATION' 2017 (%) 41
CHART 16 DISPOSSABLE AUTOINJECTOR MARKET REVENUE' 2017-2024 ($MILLION) 42
CHART 17 REUSABLE AUTOINJECTORS MARKET REVENUE' 2017-2024 ($MILLION) 43
CHART 18 AUTOINJECTOR MARKET BY REGIONAL SEGMENTATION' 2017 (%) 44
CHART 19 AUTOINJECTORS MARKET REVENUE IN NORTH AMERICA' 2017-2024 ($MILLION) 46
CHART 20 AUTOINJECTOR MARKET REVENUE IN EUROPE' 2017-2024 ($MILLION) 47
CHART 21 AUTOINJECTORS MARKET REVENUE IN ASIA PACIFIC' 2017-2024 ($MILLION) 48
CHART 22 AUTO INJECTOR MARKET REVENUE IN REST OF THE WORLD' 2017-2024 ($MILLION) 49
CHART 23 AMGEN INC.: OVERVIEW SNAPSHOT 54
CHART 24 AMGEN INC.: GEOGRAPHIC PRESENCE 55
CHART 25 AMGEN INC.: SWOT ANALYSIS 57
CHART 26 BECTON DICKINSON AND COMPANY: OVERVIEW SNAPSHOT 60
CHART 27 BECTON DICKINSON AND COMPANY: BUSINESS UNITS 61
CHART 28 BECTON DICKINSON AND COMPANY: GEOGRAPHIC REVENUE 62
CHART 29 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS 62
CHART 30 MYLAN N.V.: OVERVIEW SNAPSHOT 64
CHART 31 MYLAN N.V.: BUSINESS SEGMENTS 65
CHART 32 MYLAN N.V.: GEOGRAPHIC PRESENCE 67
CHART 33 MYLAN N.V.: SWOT ANALYSIS 67
CHART 34 BAYER AG: OVERVIEW SNAPSHOT 69
CHART 35 BAYER AG: BUSINESS UNITS 70
CHART 36 BAYER AG: GEOGRAPHICAL PRESENCE 71
CHART 37 BAYER AG: SWOT ANALYSIS 72
CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 74
CHART 39 ELI LILLY & COMPANY LTD.: BUSINESS UNITS 75
CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 76
CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 76
CHART 42 NOVARTIS AG: OVERVIEW SNAPSHOT 78
CHART 43 NOVARTIS AG: BUSINESS UNITS 81
CHART 44 NOVARTIS AG: GEOGRAPHIC PRESENCE 81
CHART 45 NOVARTIS AG: SWOT ANALYSIS 82